UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tumor angiogenesis: past, present and the near future

Carcinogenesis (New York), 2000-03, Vol.21 (3), p.505-515

KERBEL, R. S

2000

Volltextzugriff (PDF)

75 INVITED Differential and Unexpected Impact of Adjuvant Versus Metastatic Antiangiogenic Therapy

European journal of cancer (1990), 2011, Vol.47, p.S20-S21

Kerbel, R

2011

Volltextzugriff (PDF)

Clinical trials of antiangiogenic drugs : Opportunities, problems, and assessment of initial results

Journal of clinical oncology, 2001-09, Vol.19 (18), p.45s-51s

KERBEL, Robert S

2001

Volltextzugriff (PDF)

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors

The American journal of pathology, 1997-12, Vol.151 (6), p.1523-1530

1997

Volltextzugriff (PDF)

Party On: Political Parties from Hamilton and Jefferson to Trump

Second edition., 2018

Volltextzugriff (PDF)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib

British journal of cancer, 2008-05, Vol.98 (10), p.1619-1629

2008

Volltextzugriff (PDF)

S14 Antiangiogenic therapy for breast cancer: What now?

Breast (Edinburgh), 2011, Vol.20, p.S5-S5

Kerbel, R

2011

Volltextzugriff (PDF)

Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic

Annals of oncology, 2002-01, Vol.13 (1), p.12-15

2002

Volltextzugriff (PDF)

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients

British journal of cancer, 2008-04, Vol.98 (8), p.1312-1319

2008

Volltextzugriff (PDF)

NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells

British journal of cancer, 2013-07, Vol.109 (2), p.360-369

2013

Volltextzugriff (PDF)

Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis

Cancer cell, 2005, Vol.7 (1), p.101-111

2005

Volltextzugriff (PDF)

Next Generation Netroots: Realignment and the Rise of the Internet Left

1, 2016

Volltextzugriff (PDF)

Lack of Multicellular Drug Resistance Observed in Human Ovarian and Prostate Carcinoma Treated with the Proteasome Inhibitor PS-341

Clinical cancer research, 2000-09, Vol.6 (9), p.3719-3728

2000

Volltextzugriff (PDF)

Oncogenes and tumor angiogenesis : Differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts

Cancer research (Chicago, Ill.), 2000-01, Vol.60 (2), p.490-498

2000

Volltextzugriff (PDF)

Mutant ras oncogenes upregulate VEGF/VPF expression : implications for induction and inhibition of tumor angiogenesis

Cancer research (Chicago, Ill.), 1995-10, Vol.55 (20), p.4575-4580

1995

Volltextzugriff (PDF)

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis

Cancer research (Chicago, Ill.), 2001-07, Vol.61 (13), p.5090-5101

2001

Volltextzugriff (PDF)

Effect of p53 Status on Tumor Response to Antiangiogenic Therapy

Science (American Association for the Advancement of Science), 2002-02, Vol.295 (5559), p.1526-1528

2002

Volltextzugriff (PDF)

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

The Journal of clinical investigation, 2000-04, Vol.105 (8), p.R15-R24

2000

Volltextzugriff (PDF)

Reciprocal paracrine interactions between tumour cells and endothelial cells: the ‘angiogenesis progression’ hypothesis

European journal of cancer (1990), 1996-12, Vol.32 (14), p.2438-2450

1996

Volltextzugriff (PDF)

Impact of Oncogenes in Tumor Angiogenesis: Mutant K-ras up-Regulation of Vascular Endothelial Growth Factor/Vascular Permeability Factor is Necessary, but not Sufficient for Tumorigenicity of Human Colorectal Carcinoma Cells

Proceedings of the National Academy of Sciences - PNAS, 1998-03, Vol.95 (7), p.3609-3614

1998

Volltextzugriff (PDF)

Abrogation of Taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids

Cancer research (Chicago, Ill.), 1997-06, Vol.57 (12), p.2388-2393

1997

Volltextzugriff (PDF)

Interleukin-6 Undergoes Transition from Paracrine Growth Inhibitor to Autocrine Stimulator during Human Melanoma Progression

The Journal of cell biology, 1993-03, Vol.120 (5), p.1281-1288

1993

Volltextzugriff (PDF)

Clinical translation of angiogenesis inhibitors

Nature reviews. Cancer, 2002-10, Vol.2 (10), p.727-739

2002

Volltextzugriff (PDF)

‘Accidental’ anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples

European journal of cancer (1990), 2000-06, Vol.36 (10), p.1248-1257

2000

Volltextzugriff (PDF)

Marked Induction of the IAP Family Antiapoptotic Proteins Survivin and XIAP by VEGF in Vascular Endothelial Cells

Biochemical and biophysical research communications, 1999-11, Vol.264 (3), p.781-788

1999

Volltextzugriff (PDF)

1 – 25 von 496

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(437)
Mit Volltextzugriff
(432)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Tumor angiogenesis: past, present and the near future

75 INVITED Differential and Unexpected Impact of Adjuvant Versus Metastatic Antiangiogenic Therapy

Clinical trials of antiangiogenic drugs : Opportunities, problems, and assessment of initial results

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors

Party On: Political Parties from Hamilton and Jefferson to Trump

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib

S14 Antiangiogenic therapy for breast cancer: What now?

Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients

NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells

Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis

Next Generation Netroots: Realignment and the Rise of the Internet Left

Lack of Multicellular Drug Resistance Observed in Human Ovarian and Prostate Carcinoma Treated with the Proteasome Inhibitor PS-341

Oncogenes and tumor angiogenesis : Differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts

Mutant ras oncogenes upregulate VEGF/VPF expression : implications for induction and inhibition of tumor angiogenesis

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis

Effect of p53 Status on Tumor Response to Antiangiogenic Therapy

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Reciprocal paracrine interactions between tumour cells and endothelial cells: the ‘angiogenesis progression’ hypothesis

Impact of Oncogenes in Tumor Angiogenesis: Mutant K-ras up-Regulation of Vascular Endothelial Growth Factor/Vascular Permeability Factor is Necessary, but not Sufficient for Tumorigenicity of Human Colorectal Carcinoma Cells

Abrogation of Taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids

Interleukin-6 Undergoes Transition from Paracrine Growth Inhibitor to Autocrine Stimulator during Human Melanoma Progression

Clinical translation of angiogenesis inhibitors

‘Accidental’ anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples

Marked Induction of the IAP Family Antiapoptotic Proteins Survivin and XIAP by VEGF in Vascular Endothelial Cells

Suchergebnisse filtern